Bupropion Hydrobromide
Extended-release formulation of the hydrobromide salt gives bupropion hydrobromide its distinct place among bupropion products, and it is indicated for major depressive disorder and seasonal affective disorder. The pharmacology is that of the parent compound: inhibition of dopamine and noradrenaline reuptake, without the serotonergic action that characterises the SSRI and SNRI classes. That mechanistic difference underlies the lower incidence of sexual adverse effects reported relative to serotonergic antidepressants. Formulating the active moiety as an extended-release tablet rather than an immediate-release one reflects the tolerability considerations that accompany this agent. The salt is a small molecule with formula C13H19BrClNO and a molecular weight of approximately 320.7 g/mol, and it is an approved agent that has completed the final phase of clinical development.
The hydrobromide salt of bupropion, formulated as an extended-release tablet specifically for the treatment of major depressive disorder and seasonal affective disorder. Like other bupropion formulations, it inhibits dopamine and norepinephrine reuptake. It has a lower risk of sexual side effects compared to serotonergic antidepressants.
Molecular Weight
320.6500 g/mol
TPSA
29.10 Ų
Therapeutic Areas
Mechanism of Action
Norepinephrine-dopamine reuptake inhibitor (NDRI).
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Norepinephrine-dopamine reuptake inhibitor (NDRI).
2D Structure
Cite this structure
Embed this structure
SMILES
Br.CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
InChI
InChI=1S/C13H18ClNO.BrH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H
Molecular Formula
C13H19BrClNO
HBD / HBA
2 / 2
Rotatable Bonds
4
Heavy Atoms
17
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
The hydrobromide salt of bupropion, formulated as an extended-release tablet specifically for the treatment of major depressive disorder and seasonal affective disorder. Like other bupropion formulations, it inhibits dopamine and norepinephrine reuptake. It has a lower risk of sexual side effects compared to serotonergic antidepressants.
Norepinephrine-dopamine reuptake inhibitor (NDRI).
Yes, Bupropion Hydrobromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201735. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11984562. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bupropion-hydrobromide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bupropion-hydrobromide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bupropion-hydrobromide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bupropion-hydrobromide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bupropion-hydrobromide"></drugfyi-drug>